Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Laekna, Inc.

Equities

2105

KYG5340S1093

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:39 28/05/2024 BST 		5-day change 1st Jan Change
7.04 HKD +0.14% Intraday chart for Laekna, Inc. -9.16% -64.62%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
PR
Laekna Releases 2023 ESG Report
PR
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
PR
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
PR
Laekna, Inc. (2105.HK) Announces Interim Results 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.
  5. Press Releases